NVTR - ヌベクトラ (Nuvectra Corporation) ヌベクトラ

 NVTRのチャート


 NVTRの企業情報

symbol NVTR
会社名 Nuvectra Corp (ヌベクトラ)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company''s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company''s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition its NeuroNexus Technologies Inc. (NeuroNexus) subsidiary designs manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company''s neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim LLC (Algostim) and PelviStim LLC (PelviStim).   ヌベクトラは米国の医療機器メ―カ―。主に痛みや障害治療向けの神経刺激技術プラットフォ―ムの開発・商業化に従事する。同社の技術は脊髄刺激療法(SCS)や脳深部刺激療法(DBS)などに使用され、「Algovita」は体幹と手足の慢性的な痛みを治療するために開発された最初の医療機器である。本社はテキサス州プレイノ。   
本社所在地 5830 Granite Parkway Suite 1100 Plano TX 75024 USA
代表者氏名
代表者役職名
電話番号 +1 972-668-4107
設立年月日 39753
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 195人
url www.nuvectramed.com
nasdaq_url https://www.nasdaq.com/symbol/nvtr
adr_tso
EBITDA EBITDA(百万ドル) -37.39700
終値(lastsale) 23.69
時価総額(marketcap) 414792924.31
時価総額 時価総額(百万ドル) 355.07420
売上高 売上高(百万ドル) 43.29600
企業価値(EV) 企業価値(EV)(百万ドル) 350.05420
当期純利益 当期純利益(百万ドル) -39.80800
決算概要 決算概要 BRIEF: For the 26 weeks ended 30 June 2018 Nuvectra Corp revenues increased 93% to $23.7M. Net loss decreased 8% to $22.3M. Revenues reflect Nuvectra segment increase from $9.9M to $21.4M. Lower net loss reflects Nuvectra segment loss decrease of 12% to $20.7M NeuroNexus segment income increase of 83% to $267K. Basic Earnings per Share excluding Extraordinary Items increased from -$2.34 to -$1.67.

 NVTRのテクニカル分析


 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ヌベクトラ NVTR Nuvectra Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)